Virinchi Limited has informed the Exchange regarding Board meeting held on August 14, 2025.
VIRINCHI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Virinchi Limited's board approved unaudited financial results for Q1 FY26 on August 14, 2025. On a standalone basis, revenue from operations rose about 20.4% year-on-year to ₹4,007.34 lakhs (vs ₹3,328.46 lakhs in Q1 FY25), with profit after tax at ₹613.07 lakhs (vs ₹546.47 lakhs) and EPS of ₹0.60. On a consolidated basis, revenue grew more modestly to ₹7,973.66 lakhs (vs ₹7,551.97 lakhs), but net profit after tax fell sharply to just ₹36.94 lakhs (vs ₹104.84 lakhs) due to higher depreciation and finance costs. The board also discussed restructuring its US-focused FinTech SaaS unit 'QFund' into a 100% subsidiary via slump sale, with plans to divest part of it (private placement, strategic partnership, or IPO) and use proceeds to cut consolidated debt and expand the Virinchi oncology hospital chain. Auditor P. Murali & Co. issued an unmodified review report.
Standalone performance is strong with healthy revenue and profit growth, but the weak consolidated PAT and the board's move to hive off QFund to pay down debt signal rising leverage and margin pressure at the group level. Shareholders should watch the August 22 follow-up board meeting, as the proposed QFund restructuring, IPO/divestment, and debt reduction plan could materially reshape the company's structure and capital allocation.